Clinical Trials on Recurrent Fallopian Tube Mucinous Adenocarcinoma

Total 1695 results

University of Minnesota

Completed

Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Fallopian Tube Cancer | Recurrent Ovarian Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
AstraZeneca
RUSSCO (Russian Society of Clinical Oncology)

Completed

OVArian Cancer Non-Interventional Study - OVATAR (OVATAR)

Ovarian, Peritoneal, Fallopian Tube Cancer, BRCAm+ in Russia

Russian Federation
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Rectal Adenocarcinoma | Recurrent Rectal Cancer

United States
University of Pennsylvania
National Institutes of Health (NIH); Tmunity Therapeutics, a wholly owned subsidiary...

Active, not recruiting

CAR T Cells in Mesothelin Expressing Cancers

Ovarian Cancer | Fallopian Tube Cancer | Lung Adenocarcinoma | Peritoneal Carcinoma | Mesotheliomas Pleural | Mesothelioma Peritoneum

United States
Masonic Cancer Center, University of Minnesota
Celgene Corporation

Terminated

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Merck Sharp & Dohme LLC

Completed

SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Primary Peritoneal Cavity Cancer
Northwell Health
Katie Oppo Research Fund

Recruiting

HIPEC After Initial CRS in Patients Who Have Received NACT

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
University of Michigan Rogel Cancer Center

Terminated

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Emory University
Genentech, Inc.

Withdrawn

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Fallopian Tube Neoplasms | Ovarian Cancer | Primary Peritoneal
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian (SIERRA)

Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage I Colon Cancer | Stage I Rectal Cancer
North Eastern German Society of Gynaecological...
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Not yet recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8

United States
Centre Oscar Lambret
Institut National de la Santé Et de la Recherche Médicale, France

Active, not recruiting

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer (TILsOV-1805)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Fallopian Tube Cancer Stage IIIC | Fallopian Tube Cancer Stage IV

France
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

PET Imaging of Ovarian Carcinoma With 18F-FSPG

Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer and other conditions
Hoffmann-La Roche
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Completed

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Korea, Republic of, United States, Italy, Belgium, Australia, France, Austria, China, Denmark, Germany, Greece, Spain, Sweden, Japan, Russian Federation, Turkey, Norway, Brazil, Czechia, Finland, Poland, Israel
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Uterine Endometrial Cancer

United States
AstraZeneca

Completed

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India (BRCA)

Ovarian Cancer

India
Herbert Irving Comprehensive Cancer Center

Unknown

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
Northwestern University

Terminated

Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Eli Lilly and Company; Genentech, Inc.; Brigham... and other collaborators

Terminated

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Royal College of Obstetricians and Gynecologists

Completed

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA Primary Peritoneal Cancer AJCC v8 | Stage IIIA1 Fallopian Tube Cancer AJCC v8 | Stage... and other conditions

United States
Royal Marsden NHS Foundation Trust
University of Surrey

Completed

A Survivorship Care Plan for Gynaecological Cancer Patients

Sarcoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United Kingdom
Ronald Buckanovich
Genentech, Inc.

Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP Inhibitor | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Hedgehog Inhibitor

United States
John Hays
Sanofi

Unknown

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Abramson Cancer Center at Penn Medicine

Active, not recruiting

Nudge to Gynecologic Oncology

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC; ImmunoVaccine Technologies, Inc. (IMV Inc.)

Active, not recruiting

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Advanced Cancer | Primary Peritoneal Carcinoma

Canada
Abramson Cancer Center of the University of Pennsylvania

Completed

Pelvic Floor Disorders in Survivors of Gynecologic Malignancies

Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Peritoneal Cancer | Uterine Cancer

United States
Amgen

Completed

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer
AA Secord

Completed

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO23)

Ovarian Neoplasms

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Andreana Holowatyj, PhD, MSCI

Recruiting

Genetics of Appendix Cancer Study (GAP)

Appendix Cancer | Appendiceal Neoplasms | Appendix Adenocarcinoma | Appendiceal Cancer | Appendiceal Adenocarcinoma | Appendix Tumor | Appendiceal Mucinous Neoplasm | Appendiceal Carcinoid Tumor | Appendiceal Neoplasm Malignant Secondary | Appendix Mucinous Neoplasm | Appendix Cancer Metastatic | Appendix NET | Low-Grade Appendix Mucinous Neoplasm and other conditions

United States
University College, London
Merck Sharp & Dohme LLC

Active, not recruiting

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United Kingdom
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Massachusetts General Hospital; Dana-Farber...

Completed

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Canada
Krankenhaus Barmherzige Schwestern Linz

Withdrawn

HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma (HIPEC)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Austria
Masonic Cancer Center, University of Minnesota

Terminated

WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditions

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients (ACAPP)

Pseudomyxoma Peritonei

Italy
Ruijin Hospital

Not yet recruiting

Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer

Fallopian Tube Cancer | Peritoneal Cancer | Primary Ovarian Cancer
British Columbia Cancer Agency
Ozmosis Research Inc.

Unknown

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Canada

Clinical Trials on Recurrent Fallopian Tube Mucinous Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations